Treace Medical Concepts Stock Slides -56% With A 10-Day Losing Spree
Treace Medical Concepts (TMCI) stock hit day 10 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -56% return. The company has lost about $235 Mil in value over the last 10 days, with its current market capitalization at about $184 Mil. The stock remains 61.2% below its value at the end of 2024. This compares with year-to-date returns of 13.4% for the S&P 500.
Treace Medical Concepts’ recent streak saw shares plunge following a significantly lowered full-year outlook, as shifting surgeon preferences toward minimally invasive bunion solutions and broader macroeconomic headwinds weighed on elective procedure demand, prompting analyst downgrades.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact. Our take: There are a few things to fear in TMCI stock given its overall Weak operating performance and financial condition. This is aligned with the stock’s Very Low valuation because of which we think it is Fairly Priced (see Buy or Sell TMCI).
For quick background, TMCI provides innovative medical devices and the Lapiplasty procedure for foot and ankle surgeons, enabling comprehensive treatment of bunions with both cosmetic and medical benefits.
Comparing TMCI Stock Returns With The S&P 500
The following table summarizes the return for TMCI stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | TMCI | S&P 500 |
|---|---|---|
| 1D | -4.6% | -0.9% |
| 10D (Current Streak) | -56.1% | -2.6% |
| 1M (21D) | -55.1% | 0.1% |
| 3M (63D) | -59.8% | 4.1% |
| YTD 2025 | -61.2% | 13.4% |
| 2024 | -41.6% | 23.3% |
| 2023 | -44.5% | 24.2% |
| 2022 | 23.3% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 14 S&P constituents with 3 days or more of consecutive gains and 203 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 6 | 139 |
| 4D | 0 | 47 |
| 5D | 3 | 10 |
| 6D | 1 | 7 |
| 7D or more | 4 | 0 |
| Total >=3 D | 14 | 203 |
Key Financials for Treace Medical Concepts (TMCI)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $187.1 Mil | $209.4 Mil |
| Operating Income | $-51.4 Mil | $-55.7 Mil |
| Net Income | $-49.5 Mil | $-55.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $47.4 Mil | $50.2 Mil |
| Operating Income | $-17.0 Mil | $-15.7 Mil |
| Net Income | $-17.4 Mil | $-16.3 Mil |
The losing streak TMCI stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.